HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse

EMBO Molecular Medicine

Volumn 6, Issue 5, 2014, Pages 640-650

  Coltella, Nadia ^a   Percio, Stefano ^b   Valsecchi, Roberta ^a   Cuttano, Roberto ^a,e   Guarnerio, Jlenia ^a   Ponzoni, Maurilio ^a   Pandolfi, Pier Paolo ^c   Melillo, Giovanni ^d,f   Pattini, Linda ^b   Bernardi, Rosa ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SAIC FREDERICK INC   (United States)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Acute promyelocytic leukemia; Hypoxia inducible transcription factor; Leukemia initiating cells; Mouse models; PML RAR

Indexed keywords

HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL MIGRATION; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE EXPRESSION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA RELAPSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; STEM CELL; ANIMAL; CELL FUNCTION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ANIMALS; CELL PHYSIOLOGICAL PHENOMENA; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; NUCLEAR PROTEINS; RECEPTORS, RETINOIC ACID; RECOMBINANT FUSION PROTEINS; RECURRENCE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899933855     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201303065     Document Type: Article

References (35)

1. Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117: 5795-5802
2. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP (2006) PML inhibits HIF-1 alpha translation and neoangiogenesis through repression of mTOR. Nature 442: 779-785
3. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6: 665-672
4. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, Guillemin MC, Degos L, Chomienne C, de The H (1993) PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867
5. Doucas V, Brockes JP, Yaniv M, de The H, Dejean A (1993) The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc Natl Acad Sci USA 90: 9345-9349
6. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222
7. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albaek C, Schroder H, Orum H (2008) A RNA antagonist of hypoxia-inducible factor-1 alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7: 3598-3608
8. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I et al (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818
9. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M, Ferminan E, Garcia JL, Vazquez L, Gonzalez M et al (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 19: 402-409
10. Kini AR, Peterson LA, Tallman MS, Lingen MW (2001) Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97: 3919-3924
11. Lee KE, Simon MC (2012) From stem cells to cancer stem cells: HIF takes the stage. Curr Opin Cell Biol 24: 232-235
12. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM et al (2010) Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS ONE 5: e15262
13. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G et al (2010) Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 116: 3171-3179
14. Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16: 5928-5935
15. Marstrand TT, Borup R, Willer A, Borregaard N, Sandelin A, Porse BT, Theilgaard-Monch K (2010) A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia 24: 1265-1275
16. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, Stunnenberg HG (2010) PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 17: 173-185
17. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C, Pelicci PG, Muller H, Alcalay M (2005) Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene 24: 3358-3368
18. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E et al (2002) PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100: 2989-2995
19. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B et al (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14: 1333-1342
20. Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park SY, Lu J, Protopopov A, Silberstein LE (2013) Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol 15: 533-543
21. Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z, de Verneuil H, Gribben J et al (2013) HIF-2alpha Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. Cell Stem Cell 13: 549-563
22. Sanz MA, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R, Bergua JM, Leon A, Negri S, Gonzalez M et al (2008) Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 112: 3130-3134
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550
24. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, Shima H, Johnson RS, Hirao A, Suematsu M et al (2010) Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 7: 391-402
25. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A et al (2004) CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64: 2817-2824
26. Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC, Cowland JB, Borregaard N (2005) The transcriptional program of terminal granulocytic differentiation. Blood 105: 1785-1796
27. Tsuzuki S, Towatari M, Saito H, Enver T (2000) Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein. Mol Cell Biol 20: 6276-6286
28. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628
29. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S et al (2009) Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457: 51-56
30. Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M et al (2010) PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 17: 186-197
31. Wang Y, Liu Y, Malek SN, Zheng P (2011) Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8: 399-411
32. Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12
33. Wu Z, Irizarry RA (2004) Preprocessing of oligonucleotide array data. Nat Biotechnol 22: 656-658; author reply 658
34. Zhang H, Li H, Xi HS, Li S (2012) HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 119: 2595-2607
35. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M (2007) Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92: 323-331